Imaging With a PET Agent for Detection of Cancers of the Head and Neck

Sponsor: Memorial Sloan Kettering Cancer Center

Sponsor score: 60

ClinicalTrials ID:NCT03631017

Provider View

This study evaluates the safety of PARPi-FL for imaging head and neck cancer. Eligible participants are adults with confirmed squamous cell carcinoma, meeting specific health criteria. The intervention involves injecting a microdose of \[18F\]-PARPi, followed by a series of PET/CT scans to assess imaging efficacy. Exclusion criteria include impaired organ function and pregnancy.

Patient Parameters

Program Overview

The purpose of this study is to test the safety of a study drug called PARPi-FL. This drug has been tested in animals but not yet in people. The purpose of this study is to test if a PARPi-FL scan can be used to take pictures of head and neck cancer. The usual approach to imaging this cancer includes several different imaging scans, including x-rays, CT (computed tomography), MRI (magnetic resonance imaging), and PET (positron emission tomography). These tests take pictures of the cancer.

Eligibility Criteria

Inclusion Criteria

Part 1:

  • Age ≥18 years
  • ECOG performance status 0 or 1
  • Biopsy (histologically or cytologically) proven Squamos Cell Carcinoma
  • Oral cavity, oropharynx, or nasopharynx primary site
  • At least one tumor lesion on standard of care imaging with a minimum diameter of at least 1.5 cm
  • Scheduled to undergo treatment at MSKCC
  • Willingness to sign informed consent

Part 2

  • Age ≥18 years
  • ECOG performance status 0 or 1
  • Biopsy (histologically or cytologically) proven Squamous Cell Carcinoma
  • Oral cavity,oropharynx, or nasopharynx primary site
  • Scheduled to undergo surgery (neck dissection and/ or neck dissection + surgical removal of the primary) at MSK
  • Willingness to sign informed consent
  • Should have had a standard-of-care [18F]-FDG PET/CT scan before surgery (to minimize the possibility of new alterations developing between the two scans both scans should be acquired within a maximum time difference of one month).

Exclusion Criteria

  • Significantly impaired organ function that may interfere with the excretion and metabolism of the imaging agent. Specifically, patients will be excluded if they meet the following criteria:

  • Hematologic

    o Platelets <75K/mcL

  • Hepatic

    • Bilirubin >2.0 x ULN (institutional upper limits of normal)
    • AST/ALT >2.5 x ULN

  • Renal

    o Creatinine > 2.0 x ULN

  • Claustrophobia interfering with PET/CT imaging

    • Known allergy to PEG300
    • Pregnancy or breastfeeding

Locations

FACILITYZIPCITYSTATE
Memorial Sloan Kettering Cancer Center10065New YorkNew York

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.